Eintrag weiter verarbeiten
Immunotherapy for hepatitis B in the direct acting antiviral era: Reevaluating the thymosin α1 efficacy trials in the light of a combination therapy approach
Gespeichert in:
| Zeitschriftentitel: | Journal of Viral Hepatitis |
|---|---|
| Personen und Körperschaften: | , |
| In: | Journal of Viral Hepatitis, 25, 2018, 1, S. 4-9 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
Wiley
|
| Schlagwörter: |
| author_facet |
Naylor, P. H. Mutchnick, M. G. Naylor, P. H. Mutchnick, M. G. |
|---|---|
| author |
Naylor, P. H. Mutchnick, M. G. |
| spellingShingle |
Naylor, P. H. Mutchnick, M. G. Journal of Viral Hepatitis Immunotherapy for hepatitis B in the direct acting antiviral era: Reevaluating the thymosin α1 efficacy trials in the light of a combination therapy approach Virology Infectious Diseases Hepatology |
| author_sort |
naylor, p. h. |
| spelling |
Naylor, P. H. Mutchnick, M. G. 1352-0504 1365-2893 Wiley Virology Infectious Diseases Hepatology http://dx.doi.org/10.1111/jvh.12807 <jats:title>Summary</jats:title><jats:p>Hepatitis B virus (<jats:styled-content style="fixed-case">HBV</jats:styled-content>) causes both acute and chronic hepatitis and infects large numbers of individuals worldwide. Unfortunately, prediction of typical clinical outcome is problematic and there is considerable variability in the frequency, duration and severity of disease progression. The mainstay of <jats:styled-content style="fixed-case">HBV</jats:styled-content> treatment is directed towards the suppression of <jats:styled-content style="fixed-case">HBV</jats:styled-content> replication by nucleos(t)ide analogs (<jats:styled-content style="fixed-case">NUC</jats:styled-content>s). The use of immunomodulators such as α‐Interferon and thymosin α1 can, in select patients, results in elimination of both <jats:styled-content style="fixed-case">HB</jats:styled-content>sAg and <jats:styled-content style="fixed-case">HB</jats:styled-content>eAg. Given the observation that viral clearance is most effective in the presence of a strong immune response, this review summarizes data suggesting that the use of a combination of an immune modulator such as Tα1 with a highly effective <jats:styled-content style="fixed-case">NUC</jats:styled-content> may result in a more successful therapeutic approach in patients with chronic hepatitis B (CHB). Results from small studies using combination Tα1 and <jats:styled-content style="fixed-case">NUC</jats:styled-content>s are encouraging, and ongoing clinical trials combining entecavir with Tα1 are anticipated to provide important data assessing the use of a combination of Tα1 with a <jats:styled-content style="fixed-case">NUC</jats:styled-content> to achieve resolution of <jats:styled-content style="fixed-case">CHB.</jats:styled-content></jats:p> Immunotherapy for hepatitis B in the direct acting antiviral era: Reevaluating the thymosin α1 efficacy trials in the light of a combination therapy approach Journal of Viral Hepatitis |
| doi_str_mv |
10.1111/jvh.12807 |
| facet_avail |
Online |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTExMS9qdmguMTI4MDc |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTExMS9qdmguMTI4MDc |
| institution |
DE-D161 DE-Gla1 DE-Zi4 DE-15 DE-Rs1 DE-Pl11 DE-105 DE-14 DE-Ch1 DE-L229 DE-D275 DE-Bn3 DE-Brt1 |
| imprint |
Wiley, 2018 |
| imprint_str_mv |
Wiley, 2018 |
| issn |
1352-0504 1365-2893 |
| issn_str_mv |
1352-0504 1365-2893 |
| language |
English |
| mega_collection |
Wiley (CrossRef) |
| match_str |
naylor2018immunotherapyforhepatitisbinthedirectactingantiviralerareevaluatingthethymosina1efficacytrialsinthelightofacombinationtherapyapproach |
| publishDateSort |
2018 |
| publisher |
Wiley |
| recordtype |
ai |
| record_format |
ai |
| series |
Journal of Viral Hepatitis |
| source_id |
49 |
| title |
Immunotherapy for hepatitis B in the direct acting antiviral era: Reevaluating the thymosin α1 efficacy trials in the light of a combination therapy approach |
| title_unstemmed |
Immunotherapy for hepatitis B in the direct acting antiviral era: Reevaluating the thymosin α1 efficacy trials in the light of a combination therapy approach |
| title_full |
Immunotherapy for hepatitis B in the direct acting antiviral era: Reevaluating the thymosin α1 efficacy trials in the light of a combination therapy approach |
| title_fullStr |
Immunotherapy for hepatitis B in the direct acting antiviral era: Reevaluating the thymosin α1 efficacy trials in the light of a combination therapy approach |
| title_full_unstemmed |
Immunotherapy for hepatitis B in the direct acting antiviral era: Reevaluating the thymosin α1 efficacy trials in the light of a combination therapy approach |
| title_short |
Immunotherapy for hepatitis B in the direct acting antiviral era: Reevaluating the thymosin α1 efficacy trials in the light of a combination therapy approach |
| title_sort |
immunotherapy for hepatitis b in the direct acting antiviral era: reevaluating the thymosin α1 efficacy trials in the light of a combination therapy approach |
| topic |
Virology Infectious Diseases Hepatology |
| url |
http://dx.doi.org/10.1111/jvh.12807 |
| publishDate |
2018 |
| physical |
4-9 |
| description |
<jats:title>Summary</jats:title><jats:p>Hepatitis B virus (<jats:styled-content style="fixed-case">HBV</jats:styled-content>) causes both acute and chronic hepatitis and infects large numbers of individuals worldwide. Unfortunately, prediction of typical clinical outcome is problematic and there is considerable variability in the frequency, duration and severity of disease progression. The mainstay of <jats:styled-content style="fixed-case">HBV</jats:styled-content> treatment is directed towards the suppression of <jats:styled-content style="fixed-case">HBV</jats:styled-content> replication by nucleos(t)ide analogs (<jats:styled-content style="fixed-case">NUC</jats:styled-content>s). The use of immunomodulators such as α‐Interferon and thymosin α1 can, in select patients, results in elimination of both <jats:styled-content style="fixed-case">HB</jats:styled-content>sAg and <jats:styled-content style="fixed-case">HB</jats:styled-content>eAg. Given the observation that viral clearance is most effective in the presence of a strong immune response, this review summarizes data suggesting that the use of a combination of an immune modulator such as Tα1 with a highly effective <jats:styled-content style="fixed-case">NUC</jats:styled-content> may result in a more successful therapeutic approach in patients with chronic hepatitis B (CHB). Results from small studies using combination Tα1 and <jats:styled-content style="fixed-case">NUC</jats:styled-content>s are encouraging, and ongoing clinical trials combining entecavir with Tα1 are anticipated to provide important data assessing the use of a combination of Tα1 with a <jats:styled-content style="fixed-case">NUC</jats:styled-content> to achieve resolution of <jats:styled-content style="fixed-case">CHB.</jats:styled-content></jats:p> |
| container_issue |
1 |
| container_start_page |
4 |
| container_title |
Journal of Viral Hepatitis |
| container_volume |
25 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792334861628866560 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T14:35:01.855Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Immunotherapy+for+hepatitis+B+in+the+direct+acting+antiviral+era%3A+Reevaluating+the+thymosin+%CE%B11+efficacy+trials+in+the+light+of+a+combination+therapy+approach&rft.date=2018-01-01&genre=article&issn=1365-2893&volume=25&issue=1&spage=4&epage=9&pages=4-9&jtitle=Journal+of+Viral+Hepatitis&atitle=Immunotherapy+for+hepatitis+B+in+the+direct+acting+antiviral+era%3A+Reevaluating+the+thymosin+%CE%B11+efficacy+trials+in+the+light+of+a+combination+therapy+approach&aulast=Mutchnick&aufirst=M.+G.&rft_id=info%3Adoi%2F10.1111%2Fjvh.12807&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792334861628866560 |
| author | Naylor, P. H., Mutchnick, M. G. |
| author_facet | Naylor, P. H., Mutchnick, M. G., Naylor, P. H., Mutchnick, M. G. |
| author_sort | naylor, p. h. |
| container_issue | 1 |
| container_start_page | 4 |
| container_title | Journal of Viral Hepatitis |
| container_volume | 25 |
| description | <jats:title>Summary</jats:title><jats:p>Hepatitis B virus (<jats:styled-content style="fixed-case">HBV</jats:styled-content>) causes both acute and chronic hepatitis and infects large numbers of individuals worldwide. Unfortunately, prediction of typical clinical outcome is problematic and there is considerable variability in the frequency, duration and severity of disease progression. The mainstay of <jats:styled-content style="fixed-case">HBV</jats:styled-content> treatment is directed towards the suppression of <jats:styled-content style="fixed-case">HBV</jats:styled-content> replication by nucleos(t)ide analogs (<jats:styled-content style="fixed-case">NUC</jats:styled-content>s). The use of immunomodulators such as α‐Interferon and thymosin α1 can, in select patients, results in elimination of both <jats:styled-content style="fixed-case">HB</jats:styled-content>sAg and <jats:styled-content style="fixed-case">HB</jats:styled-content>eAg. Given the observation that viral clearance is most effective in the presence of a strong immune response, this review summarizes data suggesting that the use of a combination of an immune modulator such as Tα1 with a highly effective <jats:styled-content style="fixed-case">NUC</jats:styled-content> may result in a more successful therapeutic approach in patients with chronic hepatitis B (CHB). Results from small studies using combination Tα1 and <jats:styled-content style="fixed-case">NUC</jats:styled-content>s are encouraging, and ongoing clinical trials combining entecavir with Tα1 are anticipated to provide important data assessing the use of a combination of Tα1 with a <jats:styled-content style="fixed-case">NUC</jats:styled-content> to achieve resolution of <jats:styled-content style="fixed-case">CHB.</jats:styled-content></jats:p> |
| doi_str_mv | 10.1111/jvh.12807 |
| facet_avail | Online |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTExMS9qdmguMTI4MDc |
| imprint | Wiley, 2018 |
| imprint_str_mv | Wiley, 2018 |
| institution | DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Rs1, DE-Pl11, DE-105, DE-14, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1 |
| issn | 1352-0504, 1365-2893 |
| issn_str_mv | 1352-0504, 1365-2893 |
| language | English |
| last_indexed | 2024-03-01T14:35:01.855Z |
| match_str | naylor2018immunotherapyforhepatitisbinthedirectactingantiviralerareevaluatingthethymosina1efficacytrialsinthelightofacombinationtherapyapproach |
| mega_collection | Wiley (CrossRef) |
| physical | 4-9 |
| publishDate | 2018 |
| publishDateSort | 2018 |
| publisher | Wiley |
| record_format | ai |
| recordtype | ai |
| series | Journal of Viral Hepatitis |
| source_id | 49 |
| spelling | Naylor, P. H. Mutchnick, M. G. 1352-0504 1365-2893 Wiley Virology Infectious Diseases Hepatology http://dx.doi.org/10.1111/jvh.12807 <jats:title>Summary</jats:title><jats:p>Hepatitis B virus (<jats:styled-content style="fixed-case">HBV</jats:styled-content>) causes both acute and chronic hepatitis and infects large numbers of individuals worldwide. Unfortunately, prediction of typical clinical outcome is problematic and there is considerable variability in the frequency, duration and severity of disease progression. The mainstay of <jats:styled-content style="fixed-case">HBV</jats:styled-content> treatment is directed towards the suppression of <jats:styled-content style="fixed-case">HBV</jats:styled-content> replication by nucleos(t)ide analogs (<jats:styled-content style="fixed-case">NUC</jats:styled-content>s). The use of immunomodulators such as α‐Interferon and thymosin α1 can, in select patients, results in elimination of both <jats:styled-content style="fixed-case">HB</jats:styled-content>sAg and <jats:styled-content style="fixed-case">HB</jats:styled-content>eAg. Given the observation that viral clearance is most effective in the presence of a strong immune response, this review summarizes data suggesting that the use of a combination of an immune modulator such as Tα1 with a highly effective <jats:styled-content style="fixed-case">NUC</jats:styled-content> may result in a more successful therapeutic approach in patients with chronic hepatitis B (CHB). Results from small studies using combination Tα1 and <jats:styled-content style="fixed-case">NUC</jats:styled-content>s are encouraging, and ongoing clinical trials combining entecavir with Tα1 are anticipated to provide important data assessing the use of a combination of Tα1 with a <jats:styled-content style="fixed-case">NUC</jats:styled-content> to achieve resolution of <jats:styled-content style="fixed-case">CHB.</jats:styled-content></jats:p> Immunotherapy for hepatitis B in the direct acting antiviral era: Reevaluating the thymosin α1 efficacy trials in the light of a combination therapy approach Journal of Viral Hepatitis |
| spellingShingle | Naylor, P. H., Mutchnick, M. G., Journal of Viral Hepatitis, Immunotherapy for hepatitis B in the direct acting antiviral era: Reevaluating the thymosin α1 efficacy trials in the light of a combination therapy approach, Virology, Infectious Diseases, Hepatology |
| title | Immunotherapy for hepatitis B in the direct acting antiviral era: Reevaluating the thymosin α1 efficacy trials in the light of a combination therapy approach |
| title_full | Immunotherapy for hepatitis B in the direct acting antiviral era: Reevaluating the thymosin α1 efficacy trials in the light of a combination therapy approach |
| title_fullStr | Immunotherapy for hepatitis B in the direct acting antiviral era: Reevaluating the thymosin α1 efficacy trials in the light of a combination therapy approach |
| title_full_unstemmed | Immunotherapy for hepatitis B in the direct acting antiviral era: Reevaluating the thymosin α1 efficacy trials in the light of a combination therapy approach |
| title_short | Immunotherapy for hepatitis B in the direct acting antiviral era: Reevaluating the thymosin α1 efficacy trials in the light of a combination therapy approach |
| title_sort | immunotherapy for hepatitis b in the direct acting antiviral era: reevaluating the thymosin α1 efficacy trials in the light of a combination therapy approach |
| title_unstemmed | Immunotherapy for hepatitis B in the direct acting antiviral era: Reevaluating the thymosin α1 efficacy trials in the light of a combination therapy approach |
| topic | Virology, Infectious Diseases, Hepatology |
| url | http://dx.doi.org/10.1111/jvh.12807 |